Clinical trial · Interventional
Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication
Comparison of 7-day Proton Pump Inhibitor (PPI)-Clarithromycin Containing Triple Therapy and 10-day Bismuth Quadruple Therapy for Helicobacter Eradication as First-line Regimen: Randomized Controlled Trial
NCT02557932CI-TRIAL-00044561completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this randomized controlled trial, we investigate the effect of 10-day bismuth quadruple therapy in comparison with that of 7-day PPI-based standard triple as 1st line treatment for H. pylori.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Family History of Stomach Cancer | — | UNRESOLVED | — |
| Helicobacter Pylori Infection | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bismuth quadruple therapy | Drug | — | UNRESOLVED |
| Standard triple therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Standard triple therapy
- description
- 7 day-PPI based standard triple therapy
- interventionNames
- Drug: Standard triple therapy
- type
- ACTIVE_COMPARATOR
- label
- Bismuth quadruple therapy
- description
- 10 day-bismuth quadruple therapy
- interventionNames
- Drug: Bismuth quadruple therapy
Primary outcomes (1)
- measure
- H. pylori eradication rate
- timeFrame
- 8 weeks after H. pylori treatment
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women aged 18 or more including following conditions * Family history of gastric cancer * Post endoscopic resection status for early gastric cancer or adenoma * Peptic ulcer disease (benign gastric ulcer and duodenal ulcer) * Chronic gastritis * Non-ulcer dyspepsia * Healthy adults who want to receive H. pylori treatment * H. pylori positive by urea breath test, histology, or rapid urease test Exclusion Criteria: * History of H. pylori eradication therapy * History of stomach operation * Other organ cancer within 5 years * Liver cirrhosis or Hepatic insufficiency * Renal insufficiency * Current treatment for serious medical condition which may hinder participation * Contraindication or allergy history for H. pylori treatment regimens * Mental incompetence to understand and sign informed consent * Incompatible conditions to be included into the trial by investigators' decision * Inability to provide an informed consent * History of treatment for peptic ulcer disease
References
Publications (1)
- DERIVEDKim YI, Lee JY, Kim CG, Park B, Park JY, Choi IJ. Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial. BMC Gastroenterol. 2021 Mar 2;21(1):95. doi: 10.1186/s12876-021-01680-1. PMID 33653284